Building Biotech: How COVID-19 changed development forever
Posted on 09 Feb 2026
The COVID-19 pandemic transformed vaccine development, proving that safe and effective vaccines can be developed at unprecedented speed. As the life sciences industry moves beyond crisis response, the focus has shifted to how these lessons can be embedded into future vaccine development pipelines; ranging from platform technologies and regulatory agility to manufacturing resilience, global access, and public trust.
Access the Article: Rapid Vaccine Development
This article with BioProcess International examines the critical vaccine development lessons from COVID-19 that will shape future biopharmaceutical strategies, including:
- Vaccine equity and access, including regional manufacturing and technology transfer strategies
- Public trust, vaccine hesitancy, and communication strategies critical to long-term vaccine success
- Accelerated vaccine development timelines and how parallel clinical and manufacturing models are changing industry standards
- mRNA vaccine platforms and their impact on speed, scalability, and next-generation vaccine design
- Global collaboration and data sharing challenges exposed during COVID-19, and what needs to change
- Regulatory innovation, from rolling reviews to emergency authorisations and post-market surveillance
- AI and digital tools in vaccine development, supporting predictive modelling and faster design
View more blog posts
01
AI in Regulatory Affairs: What our Panel Conversations Are Actually Revealing
On a Panel at Pharma Tech Summit 2026, we discussed multiple perspectives around AI usage in biotech. Here's what we learned.
02
Building Biotech: How Nigeria can become the Vaccine Powerhouse in Africa
Lee Smith and Oyeronke Oyebanji sat down with BioProcess Insider to discuss the vaccine development and delivery practices in Nigeria: the good, the bad, and the path forward.
03
Live Attenuated Viral Vaccines Advancements
Innovation is continually taking place for a generation of new vaccines to meet patient needs across the globe.
04
Hope for Chlamydia STI Vaccine After Promising Initial Results
A vaccine to protect against Chlamydia has taken a step closer to licensure after successful phase 1 clinical trials.
05
GreyRigge Associates partners with NG Bio to accelerate VC investment
NG Bio and GreyRigge Associates Announce Strategic Partnership to Advance Biotech Innovation
06
Gene Therapy for Rare Disorders
Of the many medical breakthroughs over the past three decades, few have been as promising as gene therapy.
07
CEPI awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
CEPI awards US$21 million to Themis Bioscience.
08
Greyrigge Associates partner with SciPot Consultancy
GreyRigge Associates partner with Pharma and Biotech consultancy: SciPot Consultancy
09
Building Biotech: Being ready for AI
AI is advancing faster than biotech's frameworks were designed to support. In a recent Bioprocess Online column, our Managing Partners Lee and Andrew have documented what they think it will take for biotech to effectively integrate AI at the pace innovation now takes place.
010
Building Biotech: How COVID-19 changed development forever
The COVID-19 pandemic transformed vaccine development by compressing timelines from decades to months, proving that rapid innovation is possible through parallel development, adaptive regulation, and unprecedented global equity.
011
Building Biotech: Animal Models and Beyond - What's Next?
Animal models have long underpinned vaccine development by enabling preclinical evaluation of immunogenicity, efficacy, safety, and dose selection, and they remain integral to regulatory submissions and certain approval pathways such as the FDA Animal Rule.